ClinicalTrials.gg
Active, not recruitingNCT07497880Updated Sep 9, 2026

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

A Phase 2 interventional study of KAI-7535 and Placebo in Obesity and Overweight, sponsored by Kailera. Active, not recruiting at 36 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Kailera · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective of this study is to determine the efficacy of oral KAI-7535 once daily compared with placebo on percent change in body weight in participants living with obesity or overweight, with at least 1 weight-related comorbidity, without diabetes mellitus. Safety and tolerability and other weight-related outcomes will also be evaluated.

02

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Obesity
  • Overweight
  • Glucagon-like peptide-1
  • GLP-1
  • KAI-7535
  • Diabetes
  • Oral
03

In context

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's enrollment of 306 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Kailera is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • For participants without diabetes mellitus at screening and on Day 1, ≥30 kilograms/square meter (kg/m\^2) or BMI ≥27 kg/m\^2 and a previous diagnosis of at least 1 of the following:

    • Hypertension
    • Dyslipidemia
    • Obstructive sleep apnea
    • Cardiovascular disease
  • For participants living with type 2 diabetes mellitus and BMI ≥27 kg/m\^2 only:

    • Diagnosis of type 2 diabetes mellitus
    • On stable therapy for type 2 diabetes mellitus for at least 3 months prior to screening

Key Exclusion Criteria:

  • For participants without diabetes:

    • Laboratory evidence of diabetes
    • Taking a concomitant medication for the indication of glycemic control
  • For participants living with type 2 diabetes mellitus only:

    • History of diabetic ketoacidosis or hyperosmolar state/coma within 1 year of screening
    • History of severe hypoglycemia or hypoglycemia unawareness within 1 year of screening
    • History of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that required acute treatment
  • Started medications that may cause significant weight change within 3 months prior to screening, including tricyclic antidepressants, atypical antipsychotics, and mood stabilizers
  • Unstable weight defined as self-reported change in body weight exceeding 5% within 3 months prior to screening
  • Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid carcinoma
  • Uncontrolled hypertension or unstable cardiovascular disease
  • History of chronic or acute pancreatitis
  • Known gastric-emptying abnormality or chronic treatment with medications that directly affect gastrointestinal motility
  • History of suicide attempt
  • History of significant active or unstable major depressive disorder or other severe psychiatric disorder
  • Received treatment with semaglutide, tirzepatide, glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist, or glucagon receptor agonist within the last 3 months prior to screening

Note: Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
306 participants (actual)

Study arms

  • Experimental
    KAI-7535: Dose Schedule 1

    Participants will receive KAI-7535 once daily.

    Drug: KAI-7535

  • Experimental
    KAI-7535: Dose Schedule 2

    Participants will receive KAI-7535 once daily.

    Drug: KAI-7535

  • Experimental
    KAI-7535: Dose Schedule 3

    Participants will receive KAI-7535 once daily.

    Drug: KAI-7535

  • Experimental
    KAI-7535: Dose Schedule 4

    Participants will receive KAI-7535 once daily.

    Drug: KAI-7535

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to KAI-7535 once daily.

    Drug: Placebo

Interventions

  • DrugKAI-7535

    Oral tablets

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight at Week 44 for Participants Without Diabetes Mellitus

    Time frame: Baseline, Week 44

Secondary outcomes

  1. Change from Baseline in Body Weight at Week 44

    Time frame: Baseline, Week 44

  2. Change from Baseline in Body Mass Index (BMI) at Week 44

    Time frame: Baseline, Week 44

  3. Percentage of Participants at Week 44 with ≥5% and ≥10% Reduction in Body Weight

    Time frame: Week 44

  4. Change from Baseline in Waist Circumference at Week 44

    Time frame: Baseline, Week 44

07

Study locations

36 sites
  • Kailera Clinical Site
    Chandler, Arizona 85225, United States
  • Kailera Clinical Site
    Phoenix, Arizona 85044, United States
  • Kailera Clinical Site
    Irvine, California 92614, United States
  • Kailera Clinical Site
    Lincoln, California 95648, United States
  • Kailera Clinical Site
    Northridge, California 91325, United States
  • Kailera Clinical Site
    Hamden, Connecticut 06517, United States
  • Kailera Clinical Site
    Jacksonville, Florida 32256, United States
  • Kailera Clinical Site
    Jupiter, Florida 33458, United States
  • Kailera Clinical Site
    Palm Springs, Florida 33461, United States
  • Kailera Clinical Site
    Pembroke Pines, Florida 33024, United States
  • Kailera Clinical Site
    Decatur, Georgia 30030, United States
  • Kailera Clinical Site
    Chicago, Illinois 60640, United States
  • Kailera Clinical Site
    Skokie, Illinois 60077, United States
  • Kailera Clinical Site
    South Bend, Indiana 46617, United States
  • Kailera Clinical Site
    Kenner, Louisiana 70065, United States
  • Kailera Clinical Site
    Garden City, Michigan 48135, United States
  • Kailera Clinical Site
    Jefferson City, Missouri 65109, United States
  • Kailera Clinical Site
    Kansas City, Missouri 64151, United States
  • Kailera Clinical Site
    Spartanburg, South Carolina 29303, United States
  • Kailera Clinical Site
    Knoxville, Tennessee 37909, United States
  • Kailera Clinical Site
    Austin, Texas 78705, United States
  • Kailera Clinical Site
    Austin, Texas 78757, United States
  • Kailera Clinical Site
    Brownsville, Texas 78520, United States
  • Kailera Clinical Site
    Farmers Branch, Texas 75234, United States
  • Kailera Clinical Site
    Fort Worth, Texas 76135, United States
  • Kailera Clinical Site
    Mesquite, Texas 75149, United States
  • Kailera Clinical Site
    San Antonio, Texas 78222, United States
  • Kailera Clinical Site
    San Antonio, Texas 78229, United States
  • Kailera Clinical Site
    San Antonio, Texas 78240, United States
  • Kailera Clinical Site
    Sugar Land, Texas 77479, United States
  • Kailera Clinical Site
    Sandy City, Utah 84093, United States
  • Kailera Clinical Site
    Dee Why, New South Wales 2100, Australia
  • Kailera Clinical Site
    Miranda, New South Wales 2228, Australia
  • Kailera Clinical Site
    Wollongong, New South Wales 2500, Australia
  • Kailera Clinical Site
    Norwood, South Australia 5067, Australia
  • Kailera Clinical Site
    Altona N., Victoria 3025, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2027, 15 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 15 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Mar 27, 2026
StartActual
Apr 6, 2026
Primary completionEst.
Jul 7, 2027
CompletionEst.
Jul 7, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07497880
Lead sponsor
Kailera
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Apr 6, 2026
Primary completion
Jul 7, 2027 (estimated)
Completion
Jul 7, 2027 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion